Hearing loss: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• GLP-1 0
• PD-1 0
• SGLT2 0
• ABL1 0
• AMPK 0
• CGRP 0
• ERK 0
• JAK 0
• mTOR 0
• NLRP3 0
• SHP2 0
• STAT3 0
• STING 0
• VEGF 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  REstoring VIsion via native-Code-Aligned Neurostimulation (REVICAN)

  Univerzita Karlova· Praha 1, Csehország· EU contribution 731 460 EUR· until 2030. szept.· 9 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Visual Hearing for Context-Aware Cognitive Audio Technology (WeHear)

  Danmarks Tekniske Universitet· Kongens Lyngby, Dánia· EU contribution 5 411 208 EUR· until 2029. aug.· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Unlocking bio-inspired machine hearing and accelerating personalized hearing technologies (InSilicoEars)

  Universiteit Gent· Gent, Belgium· EU contribution 1 999 712 EUR· until 2031. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Watts in my ear? Unravelling the power source of mammalian hearing. (ActivEAR)

  Universidad Autonoma de Madrid· Madrid, Spanyolország· EU contribution 1 923 556 EUR· until 2031. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Advancing a scalable and multifactorial exosome therapy to address the unmet needs of drug-induced hearing loss (EXO-OTOProtect)

  Exogenus Therapeutics Sa· Cantanhede, Portugália· EU contribution 500 000 EUR· until 2028. febr.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Elucidating the Evolution of Endothermy through an Endolymphomics Approach (ENDOMICS)

  Instituto Superior Tecnico· Lisboa, Portugália· EU contribution 207 183 EUR· until 2028. máj.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  REHEAR: Reverse Engineered Hearing Evaluation for Auditory-neuropathy Recognition

  Universitat Zurich· Zurich, Svájc· EU contribution 307 959 EUR· until 2028. ápr.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Saving vision: expanding use of lentiviral gene therapy to fight blindness (EuroVision)

  Medizinische Hochschule Hannover· Hannover, Németország· EU contribution 150 000 EUR· until 2027. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  High-resolution auditory restoration by a brain implant operated with a bio-mimetic deep encoder (BRAINCODER)

  Centre National de la Recherche Scientifique Cnrs· Paris, Franciaország· EU contribution 150 000 EUR· until 2027. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Music Processing for Cochlear Implants Based on Auditory and Neural Modelling (MUSICIAN)

  Ruhr-Universitaet Bochum· Bochum, Németország· EU contribution 280 752 EUR· until 2028. márc.· 2 countries

10 of 21 running projects, newest first. Listed amounts together: 41,9 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 4
• Organoids 12
• Mendelian Randomization Analysis 16
• CRISPR-Cas Systems 6
• Gene Expression Profiling 18
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 6
• Exome Sequencing 75
• Proteomics 10
• Metabolomics 9
• Mass Spectrometry 1
• Immunohistochemistry 12
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 162
• Machine Learning 37
• Deep Learning 20
• Cohort Studies 95
• Genome-Wide Association Study 23

• Biomarkers of Subjective Tinnitus Presence and Clinical Burden: A Systematic Review.

  Hear Res, 2026. aug.

• Multimodal biomarkers in idiopathic sudden sensorineural hearing loss: integrating immune, vascular, and metabolic perspectives for precision medicine.

  Front Immunol, 2026. júl.

• Underwater noise exposure induces auditory threshold shifts and metabolomic alterations in the inner ear endolymph of European sea bass.

  Environ Pollut, 2026. júl.

• Metabolomic signature reveals dysregulated lipoprotein profile in m.3243A>G carriers: a case-control study.

  Metabolomics, 2026. júl.

• Metabolic profiling of DNA methylation age acceleration, associations with hearing loss and interaction with genetic susceptibility.

  Free Radic Biol Med, 2026. jún.

• Metabolomics Highlights Reduced Glutamate and Acetylcarnitine in the Amniotic Fluid of Cytomegalovirus-Infected Pregnant Women.

  J Proteome Res, 2026. márc.

• A plasma metabolomic fingerprint of moderate or severe hearing loss.

  Metabolomics, 2026. febr.

• Gut-Metabolome-Proteome Interactions in Age-Related Hearing Loss: Insights from Fecal Microbiota Transplantation and Multi-Omics Analyses.

  Adv Sci (Weinh), 2026. jan.

• Metabolomic profiling reveals potential biomarkers for sudden sensorineural hearing loss.

  Sci Prog, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.